123 related articles for article (PubMed ID: 9260478)
1. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints.
Pittrow L; Penk A
Mycoses; 1997; 40(1-2):25-32. PubMed ID: 9260478
[TBL] [Abstract][Full Text] [Related]
2. [Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem].
Pittrow L; Penk A
Mycoses; 1996; 39 Suppl 2():58-65. PubMed ID: 9198747
[TBL] [Abstract][Full Text] [Related]
3. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
4. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Rex JH; Pfaller MA; Galgiani JN; Bartlett MS; Espinel-Ingroff A; Ghannoum MA; Lancaster M; Odds FC; Rinaldi MG; Walsh TJ; Barry AL
Clin Infect Dis; 1997 Feb; 24(2):235-47. PubMed ID: 9114154
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
[TBL] [Abstract][Full Text] [Related]
7. Fluconazole: optimized antifungal therapy based on pharmacokinetics.
Silling G
Mycoses; 2002; 45 Suppl 3():39-41. PubMed ID: 12690970
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.
Wenisch C; Moore CB; Krause R; Presterl E; Pichna P; Denning DW
J Clin Microbiol; 2001 Jul; 39(7):2458-62. PubMed ID: 11427554
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis].
Viudes A; Cantón E; Pemán J; López-Ribot JL; Gobernado M
Rev Esp Quimioter; 2002 Mar; 15(1):32-42. PubMed ID: 12582435
[TBL] [Abstract][Full Text] [Related]
10. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection].
Ruhnke M; Schmidt-Westhausen A; Trautmann M
Mycoses; 1996; 39 Suppl 2():47-50. PubMed ID: 9198745
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.
Han S; Kim J; Yim H; Hur J; Song W; Lee J; Jeon S; Hong T; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 Feb; 57(2):1006-11. PubMed ID: 23254425
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
14. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
Ghannoum MA
Clin Infect Dis; 1996 May; 22 Suppl 2():S161-5. PubMed ID: 8722845
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
16. Susceptibility testing of fungi and correlation with clinical outcome.
Ghannoum MA
J Chemother; 1997 May; 9 Suppl 1():19-24. PubMed ID: 9248959
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
Ozcan SK; Mutlu B; Dündar D; Willke A
Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
[TBL] [Abstract][Full Text] [Related]
18. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.
Cuesta I; Bielza C; Larrañaga P; Cuenca-Estrella M; Laguna F; Rodriguez-Pardo D; Almirante B; Pahissa A; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2009 Jul; 53(7):2949-54. PubMed ID: 19433568
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
Debruyne D
Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility testing of Candida species: comparison of NCCLS microdilution method with Fungitest.
Willinger B; Apfalter P; Hirschl AM; Makristathis A; Rotter M; Seibold M
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):11-5. PubMed ID: 11025178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
